Pain Management with Dexmedetomidine in Patients with Traumatic Rib Fractures
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on December 5th, 2025
|
Pain control in patients with traumatic rib fractures is difficult to achieve. Common options such as acetaminophen, NSAIDs, and muscle relaxants often provide insufficient relief, while stronger agents like opioids carry risks of addiction and respiratory depression. To explore alternative strategies, researchers at the University of California conducted a study evaluating dexmedetomidine for pain management in this population.
The phase 3 trial enrolled 41 intensive care unit patients with a median age of 62 years who had sustained three or more rib fractures. Participants were randomized to receive either an intravenous placebo or dexmedetomidine at 0.4 μg per kilogram of body weight for 48 hours. Use of NSAIDs was left to the discretion of treating physicians, while ketamine and lidocaine infusions were provided for uncontrolled pain. Dexmedetomidine produces analgesia and sedation by activating alpha-2 adrenoceptors in the brain and spinal cord, which suppresses norepinephrine release and dampens sympathetic activity.
The study found that dexmedetomidine did not improve pain outcomes. Lengths of stay in both the hospital and the ICU were similar—approximately 9 and 4 days, respectively. Pain ratings on a 1–10 scale did not differ between groups, and morphine use was comparable. Dexmedetomidine was also associated with a higher incidence of bradycardia and hypotension. The investigators suggested that the absence of measurable benefit may be due to the small sample size and the relatively low dexmedetomidine dose, which was about one-third of the typical dosage used for sedation.
The phase 3 trial enrolled 41 intensive care unit patients with a median age of 62 years who had sustained three or more rib fractures. Participants were randomized to receive either an intravenous placebo or dexmedetomidine at 0.4 μg per kilogram of body weight for 48 hours. Use of NSAIDs was left to the discretion of treating physicians, while ketamine and lidocaine infusions were provided for uncontrolled pain. Dexmedetomidine produces analgesia and sedation by activating alpha-2 adrenoceptors in the brain and spinal cord, which suppresses norepinephrine release and dampens sympathetic activity.
The study found that dexmedetomidine did not improve pain outcomes. Lengths of stay in both the hospital and the ICU were similar—approximately 9 and 4 days, respectively. Pain ratings on a 1–10 scale did not differ between groups, and morphine use was comparable. Dexmedetomidine was also associated with a higher incidence of bradycardia and hypotension. The investigators suggested that the absence of measurable benefit may be due to the small sample size and the relatively low dexmedetomidine dose, which was about one-third of the typical dosage used for sedation.